At the beginning of 2024, good news came from the World Intellectual Property Organization. The "13-OXIDIZED INGENOL DERIVATIVE AND USE THEREOF" applied by the Tianjin Pharmaceutical Darentang Traditional Chinese Medicine Research Institute was authorized for European invention patents, becoming the fourth key region to be authorized after China, the United States, and Australia.

This patent was independently developed by the Institute of Traditional Chinese Medicine of Tianjin Pharmaceutical Darentang Group. The research team used the 13-oxygenol parent core derived from the traditional Chinese medicine Kansui as the starting material to develop a series of 13-oxygenol ester derivatives with dual mechanisms of direct cytotoxicity and immune stimulation., have good application prospects in anti-tumor and medicinal cosmetic fields such as skin precancerous lesions, viral infectious skin diseases and skin cancer, and have advantages of high efficiency and low toxicity compared with marketed drugs and existing natural products.

The research results applied for compound and use patents to China, the United States, Europe and Australia through the PCT (Patent Cooperation Treaty) channel. Among them, Australia, China and the United States have obtained patent authorizations in July 2021, December 2022, and September 2023 respectively. The authorization of this European patent application means that this patent is authorized in all predetermined key countries and regions.

The Institute of Traditional Chinese Medicine has always adhered to the principal of"Laying solid foundation, Innovating and moving forward", focusing on "serving production, supporting marketing, and leading the future", continued to improve its independent research and development capabilities and innovation capabilities, strengthened the protection and application of intellectual property rights, and developed more high-value patented technologies., helping Tianjin Pharmaceutical Darentang become a leader in innovative Chinese medicine.